Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission. Issue 11 (8th September 2022)

• Record Type: Journal Article
• Authors: Short, Nicholas J.; Macaron, Walid; Kadia, Tapan; Dinardo, Courtney; Issa, Ghayas C.; Daver, Naval; Wang, Sa; Jorgensen, Jeff; Nguyen, Daniel; Bidikian, Aram; Patel, Keyur P.; Loghavi, Sanam; Konopleva, Marina; Yilmaz, Musa; Jabbour, Elias; Maiti, Abhishek; Abbas, Hussein A.; Shpall, Elizabeth; Popat, Uday; Al‐Atrash, Gheath; Pierce, Sherry; Kantarjian, Hagop M.; Ravandi, Farhad
• Is Part Of: American journal of hematology. Volume 97:Issue 11(2022)
• Page Start: E408
• Page End: E411
• Publication Date: 2022-09-08
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.26698
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract : Recurrence of MRD in AML is associated with imminent relapse unless intervened upon. Change in chemotherapy regimen and/or immediate transplant improve outcomes.